Long-term effect of low molecular weight heparin on serum lipids in hypertriglyceridemic chronic hemodialysis patients

Journal of Nephrology

Volumn 10, Issue 2, 1997, Pages 111-114

  Vlassopoulos, Dimosthenis ^a   Noussias, Christos ^a   Hadjipetrou, Athena ^a   Arvanitis, Dimitrios ^a   Logothetis, Emmanuel ^a   Magana, Panayota ^a   Katopodis, Konstantinos ^a   Hadjiconstantinou, Valsamakis ^a  

^a AMALIA FLEMING GENERAL HOSPITAL   (Greece)

Author keywords

hemodialysis; hyperlipidemia; low molecular weight heparin

Indexed keywords

LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; FEMALE; HEMODIALYSIS; HUMAN; HYPERLIPIDEMIA; HYPERTRIGLYCERIDEMIA; INTRAARTERIAL DRUG ADMINISTRATION; MALE;

ADULT; AGED; CHRONIC DISEASE; FEMALE; HEPARIN, LOW-MOLECULAR-WEIGHT; HUMANS; HYPERLIPIDEMIAS; LIPIDS; MALE; MIDDLE AGED; RENAL DIALYSIS;

EID: 0030927840     PISSN: 11218428     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (22)

1. Schrader J, Anderson LO, Armstrong VW, Kundt M, Stibbe W, Scheller F. Lipolytic effects of heparin and low molecular weight heparin and their importance in hemodialysis. Semin Thromb Hemost 1990; 16: 41-45.
2. Ljungberg B, Blomback M, Johnson H, Lins L-E. A single dose of a low molecular weight heparin fragment for anticoagulation during hemodialysis. Clin Nephrol 1987; 27: 31-35.
3. Sugiyama T, Natsuga T. Pharmacological studies of low molecular weight heparin (LHG). Nippon Yakurigaku Zasshi 1991; 98: 301-310.
4. Deuber HJ, Schulz W. Reduced lipid concentrations during four years of dialysis with low molecular weight heparin. Kidney Int 1991; 40: 496-500.
5. Schmitt Y, Schneider H. Low molecular weight heparin (LMWH): influence on blood lipids in patients on chronic hemodialysis. Neph Dial Transpl 1993; 8: 438-444.
6. Appel G. Lipid abnormalities in renal disease. Kidney Int 1991; 39: 169-183.
7. Goldberg AP, Applebaum-Bowden DM, Bierman EL et al. Increase in lipoprotein lipase during clofibrate treatment of hypertriglyceridemia in patients on hemodialysis. N E J M 1979; 301: 1073-1076.
8. Chan MK, Persaud J, Varguese Z, Moorhead JF. Pathogenic roles of post-heparin lipases in lipid abnormalities in hemodialysis patients. Kidney Int 1984; 25: 812-818.
9. Hahn R, Oette K, Mondorf H, Finke K, Sieberth HG. Analysis of cardiovascular risk factors in chronic hemodialysis patients with special attention to the hyperlipoproteinemias. Atherosclerosis 1983; 48: 279-88.
10. Shoji T, Nishizava Y, Nishitani H, Yamakawa M, Morii H. Impaired metabolism of high density lipoprotein in uremic patients. Kidney Int 1992; 41: 1653-61.
11. Goldberg AP, Harter HR, Patsch W, et al. Racial differences in plasma high density lipoproteins in patients receiving hemodialysis. A possible mechanism for accelerated atherosclerosis in white man. NEJM 1983; 308: 1245-52.
12. Akmal M, Kasim SE, Soliman AE, Massry SG. Excess parathyroid hormone adversely affects lipid metabolism in chronic renal failure. Kidney Int 1990; 37: 854-8.
13. Senti M, Romero R, Pedro-Botet J, Pelegri A, Nogues X, Rubies-Prat J. Lipoprotein abnormalities in hyperlipidemic and normolipidemic men on hemodialysis with chronic renal failure. Kidney Int 1992; 41: 1394-9.
14. Attman PO, Alaupovic P. Lipid and Apolipoprotein profile of uremic dyslipoproteinemia. Relation to renal function and dialysis. Nephron 1991; 57: 401-10.
15. Akiba T, Tachibana K, Ozawa K, et al. Long-term use of low molecular weight heparin ameliorates hyperlipidaemia in patients on hemodialysis. ASAIO Journal 1992; 38: M326-30.
16. Arnadottir M, Thysell H, Dallongeville J, Fruchart JC, Nilsson-Ehle P. Evidence that reduced lipase activity is not a primary pathogenetic factor for hypertriglyceridaemia in renal failure. Kidney Int 1995; 48: 779-84.
17. Stenvinkel P. Low molecular weight heparin, does it favourably affect lipid levels? Nephrol Dial Transplant 1995; 10: 16-8.
18. Dasgupta A, Hussain S, Ahmad S. Increased lipid peroxidation in patients on maintenance hemodialysis. Nephron 1992; 60: 56-9.
19. Seres DS, Strain GW, Hashim SA, Goldberg IJ, Levin NW. Improvement of plasma lipoprotein profiles during high-flux dialysis. J Am Soc Nephrol 1993; 3: 1409-15.
20. Josephson MA, Fellner SK, Dasgupta A. Improved lipid profiles in patients undergoing high flux hemodialysis. Am J Kid Dis 1992; 20: 361-6.
21. Arnadottir M, Nilsson-Ehle P. Parathyroid hormone is not an inhibitor of lipoprotein lipase activity. Nephrol Dial Transplant 1994; 9: 1586-9.
22. Pollock C, Wyndham R, Collet PV, et al. Effects of erythropoietin therapy on the lipid profile in end stage renal failure. Kidney Int 1994; 45: 897-902.